See how some students have opted for a unique conclusion to their studies.
20% subcutaneous immunoglobulin therapy.
Two new best practices, a new classification, and 5 updated existing rules.
Lack of Quality Evidence Around Cannabis Use Complicates Patient Management in the Health-System Setting
Takeaways from a roundtable at ASHP 2019.
Presented at the ASHP Midyear 2019.
Based upon results from a military population study presented at ASHP 2019.
The pair were recognized for contributions to the association and industry.
Results at ASHP 2019 suggest potential for administration errors without proper guidance.
Biosimilar to Remicade
Allergan’s positive phase 3 trial results indicate a potential use for the CGRP receptor agonist.